Zabadinostat (Standard)
Zabadinostat (Standard) is the analytical standard of Zabadinostat (HY-100748). This product is intended for research and analytical applications. Zabadinostat (CXD101) is a potent, selective and orally active class I HDAC inhibitor with IC50s of 63 nM, 570 nM and 550 nM for HDAC1, HDAC2 and HDAC3, respectively. Zabadinostat has no activity against HDAC class II. Zabadinostat has antitumor activity.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 98%
- CAS No.: 934828-12-3
- Formule: C24H29N5O
- Masse moléculaire:403.52
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Pureté et documentation
-
Help & FAQs
-
HY-100748
ZabadinostatHDAC1/2/3 Inhibitor -
HY-15149
RomidepsinHDAC Inhibitor -
HY-15144
Trichostatin AHDAC Class I/II Inhibitor -
HY-N0931
Santacruzamate AHDAC2 Inhibitor -
HY-18361
TMP195HDAC Inhibitor -
HY-15994
CitarinostatHDAC6 Inhibitor -
HY-15224
PCI-34051Apoptosis Inducer -
HY-10990
AbexinostatHDAC/MBLAC2 Inhibitor -
HY-109015
TucidinostatHDAC Inhibitor -
HY-16914
MC1568HDAC Inhibitor -
HY-13428
TubacinHDAC6 Inhibitor -
HY-16699
Nexturastat AHDAC6 Inhibitor
Product Information
Information
Application
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 934828-12-3
-
Masse moléculaire 403.52
-
Formule C24H29N5O
-
SMILES
O=C(NC1=C(N)C=CC=C1)C2=CC=C(C3CCN(CC4=CN(C)N=C4C)CC3)C=C2
-
Synonyms
CXD101 (Standard)
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Eyre TA, et al. Predictive biomarkers for disease sensitivity in lymphoma - the holy grail for HDAC inhibitors? Oncotarget. 2018 Dec 18;9(99):37280-37281. [Content Brief]
[2]. Eyre TA, et al. A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer. Cancer. 2019 Jan 1;125(1):99-108. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Zabadinostat (Standard) Related Classifications
HY-100748R Related Classifications
Powered by Bioz